Description

Kadcyla Injection 160mg (Trastuzumab Emtansine) – Uses, Dosage & Side Effects

Kadcyla 160mg Injection (generic name: Trastuzumab Emtansine / Ado-Trastuzumab Emtansine) is an advanced targeted therapy used for the treatment of HER2-positive breast cancer. Manufactured by Roche Pakistan Pvt Ltd, this medicine is available in a single vial injection (20 mg/ml concentration) and belongs to the class of antineoplastic monoclonal antibodies.

Key Features

• Brand Name: Kadcyla

• Generic Name: Trastuzumab Emtansine

• Strength: 160 mg (20 mg/ml)

• Form: Injection (IV infusion)

• Pack Size: 1 vial

• Manufacturer: Roche Pakistan Pvt Ltd

• Therapeutic Class: Targeted Anticancer Therapy

How Kadcyla Works

Kadcyla is an antibody-drug conjugate (ADC) that combines the HER2-targeting action of trastuzumab with the chemotherapy agent DM1 (a maytansine derivative).

• HER2 Targeting: Binds specifically to HER2-positive cancer cells and blocks growth signals.

• Drug Delivery: Once bound, the drug is internalized and releases DM1 inside cancer cells.

• Cytotoxic Effect: DM1 disrupts microtubules, halting cell division and causing cancer cell death.

• Reduced Side Effects: Targets cancer cells while minimizing damage to healthy tissues.

Indications (Uses)

Kadcyla is prescribed for:

• Metastatic HER2-positive breast cancer in patients previously treated with trastuzumab and taxane-based chemotherapy.

• Adjuvant therapy in patients with early breast cancer who have residual invasive disease after neoadjuvant trastuzumab + taxane treatment.

Recommended Dosage

• Standard Dose: 3.6 mg/kg body weight, administered via IV infusion every 3 weeks (21-day cycle).

• First Infusion: 90 minutes (monitored for reactions).

• Subsequent Infusions: May be given over 30 minutes if tolerated.

• Duration: Continue until disease progression or unacceptable toxicity.

Side Effects

Common side effects include:

• Fatigue and nausea

• Infusion-related reactions

• Liver enzyme elevation (hepatotoxicity)

• Cardiac dysfunction (requires heart monitoring)

• Thrombocytopenia (low platelet count)

Safety & Precautions

• Cardiac Monitoring: Regular heart function tests (LVEF).

• Liver Function: Monitor LFTs before and during therapy.

• Pregnancy: Not recommended; effective contraception required during and 7 months after treatment.

• Breastfeeding: Should be avoided.

• Drug Interactions: Inform your doctor about antibiotics, antifungals, or antiviral medicines being used.

Dietary & Lifestyle Advice

• Avoid: Alcohol, processed meats, sugary drinks, fried foods, and high-sodium snacks.

• Recommended Foods: Fresh fruits (berries, citrus), cruciferous vegetables, leafy greens, omega-3-rich fish, nuts, seeds, and whole grains.

• Hydration: Drink plenty of water and consider herbal teas.

• Small Frequent Meals: Helps manage nausea and digestive discomfort.

Storage Instructions

• Store at 2°C–8°C (36°F–46°F).

• Keep away from light.

• Do not freeze.

• Use reconstituted solution promptly.

Patient Reviews & Experience

Patients report improved treatment outcomes with Kadcyla compared to standard chemotherapy. While side effects such as fatigue and nausea are common, they are generally manageable under medical supervision. Many patients highlight better quality of life during therapy.